Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrical and Structural Atrial Remodeling Identifies a High-Risk Phenotype in Embolic Stroke of Undetermined Source.

JACC. Advances·2026
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026
Same author

Cardiac Amyloidosis: Pathogenesis, Diagnosis, and Treatment.

Deutsches Arzteblatt international·2026
Same author

Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept.

Pulmonary circulation·2026
Same author

Relationship between culprit lesion high-risk plaque features and adverse cardiovascular outcome at two years follow-up in patients with acute coronary syndrome. Insights from the OPTICO-ACS study.

The international journal of cardiovascular imaging·2026
Same author

Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine.

European journal of heart failure·2026

Related Experiment Video

Updated: Jun 13, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

STAT3 and cardiac remodeling.

Arash Haghikia1, Britta Stapel, Melanie Hoch

  • 1Department of Cardiology and Angiology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Heart Failure Reviews
|April 22, 2010
PubMed
Summary

The signal transducer and activator of transcription 3 (STAT3) protein influences heart remodeling and function. STAT3 signaling is a potential therapeutic target for cardiac conditions.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cell Signaling

Background:

  • The signal transducer and activator of transcription 3 (STAT3) protein plays a role in cardiomyocyte protection and hypertrophy.
  • STAT3 signaling impacts cardiac remodeling through paracrine pathways affecting vasculature and extracellular matrix.

Purpose of the Study:

  • To review the role of STAT3 signaling in cardiac remodeling.
  • To summarize current understanding of STAT3's function in cardiac physiology and pathophysiology.
  • To discuss STAT3 as a potential therapeutic target for cardiac remodeling.

Main Methods:

  • Review of in vitro and in vivo studies.
  • Analysis of experimental and clinical data on STAT3 in cardiac remodeling.
  • Literature synthesis on STAT3's molecular and cellular mechanisms.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Related Experiment Videos

Last Updated: Jun 13, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Main Results:

  • STAT3 is involved in cardiomyocyte protection, hypertrophy, and cardiac remodeling.
  • STAT3 is activated by various factors like cytokines, growth factors, and ischemia.
  • STAT3 functions as a signaling molecule, transcription factor, and mitochondrial protein.

Conclusions:

  • STAT3 signaling is crucial for cardiac remodeling in both physiological and pathological states.
  • STAT3's multifaceted roles in the heart highlight its significance.
  • Targeting STAT3 signaling presents a promising therapeutic strategy for cardiac remodeling.